Cancer Panels use next generation sequencing (NGS) technology to target specific genes or mutations that have established relevancy to a particular cancer phenotype. NGS facilitates sequencing of large genomic regions, high numbers of genes, and/or high numbers of samples in a single, efficient and cost-effective assay.
Soluble cytokine biomarkers are the master regulators of cell-to-cell communication-- the means by which one cell tells another what to do or where to go. Determining the biomarker signature...
The continued rapid expansion of immunotherapies, including both in vivo and ex vivo therapeutics, has driven the development and adoption of novel tools to study, asses and understand these...
Date: September 28, 2020 Time: 5:00pm (PDT), 8:00am (HKT), 9:00am (JST) Although there have been dramatic advances in the field of single-cell sequencing, current methods cannot be applied t...
The regulated cannabis industry has existed in the US for nearly a decade. New medical and adult-use markets will most likely experience similar maturation and periods of volatility as state...
Suspension by day, imaging by night: how to efficiently manage your system and optimize utilization Presented By: Jared K. Burks, PhD Mass cytometry, be it suspension or imaging, opens the d...
On measuring photons and ions: Impact on panel design, signal detection and data quality 10:30–11:00 am PDT Presented By: Tim Bushnell, PhD, MBA Monitoring immunotherapy with a mass cy...
Multiplex immunophenotyping technologies are indispensable for a deeper understanding of biological systems. Until recently, high-dimensional cellular analyses implied the loss of tissue con...
MicroRNA(miRNA) are short non-coding single stranded RNA molecules that regulate gene expression at the post transcriptional level. They are known to play a critical role in multiple biologi...
Lung cancer management has changed over the last few years with several actionable targets being recognised and mandated in the optimal management of these patients. The biomarker ordering p...
Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
Join us and hear from two Luminex® experts on our flexible solutions for molecular diagnostics. Dr. Sherry Dunbar and Dr. Aaron Benfield will describe our NxTAG® bead-based nucleic a...
A key step in the clinical production of CAR T cells is the expansion of engineered T cells. To generate enough cells for viable adoptive cell therapy, cells must be robustly stimulated, whi...
Background: Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Despite recent advancements in the treatment of AML, approximately 50% of pat...
Metastatic prostate cancer (mPC) is a phenotypically diverse disease with poor responses to immune based therapeutics. Development of immunotherapeutic strategies for mPC is hampered by the...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
Precision medicine is the paradigm to develop treatments for patients based on molecular-targets that are effective in vivo when administered. In addition to identifying the molecular and ce...
Targeted therapies for cancer are increasingly being developed as an alternative for, and in addition to, immunotherapy. Altered tumor signaling can be exploited to single-out cancer cells f...
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with poor outcome. It is expected to be the leading cause of cancer-related death in 2030. The unique microe...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Operational barriers like complicated workflows and long turnaround times have hindered broad adoption of next-generation sequencing (NGS) in clinical oncology research. The new Ion Torrent...
Learning Objectives: 1. Participants will become familiar with basic aspects of the user experience with the Genexus system 2. Participants will learn about preliminary studies using a targe...
The evolution of clinical trial design in oncology reflects the current clinical paradigm of personalized medicine, weighing both histology and molecularly-defined biomarkers as the pillars...
Soluble cytokine biomarkers are the master regulators of cell-to-cell communication-- the means by which one cell tells another what to do or where to go. Determining the biomarker signature...
The continued rapid expansion of immunotherapies, including both in vivo and ex vivo therapeutics, has driven the development and adoption of novel tools to study, asses and understand these...
Date: September 28, 2020 Time: 5:00pm (PDT), 8:00am (HKT), 9:00am (JST) Although there have been dramatic advances in the field of single-cell sequencing, current methods cannot be applied t...
The regulated cannabis industry has existed in the US for nearly a decade. New medical and adult-use markets will most likely experience similar maturation and periods of volatility as state...
Suspension by day, imaging by night: how to efficiently manage your system and optimize utilization Presented By: Jared K. Burks, PhD Mass cytometry, be it suspension or imaging, opens the d...
On measuring photons and ions: Impact on panel design, signal detection and data quality 10:30–11:00 am PDT Presented By: Tim Bushnell, PhD, MBA Monitoring immunotherapy with a mass cy...
Multiplex immunophenotyping technologies are indispensable for a deeper understanding of biological systems. Until recently, high-dimensional cellular analyses implied the loss of tissue con...
MicroRNA(miRNA) are short non-coding single stranded RNA molecules that regulate gene expression at the post transcriptional level. They are known to play a critical role in multiple biologi...
Lung cancer management has changed over the last few years with several actionable targets being recognised and mandated in the optimal management of these patients. The biomarker ordering p...
Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
Join us and hear from two Luminex® experts on our flexible solutions for molecular diagnostics. Dr. Sherry Dunbar and Dr. Aaron Benfield will describe our NxTAG® bead-based nucleic a...
A key step in the clinical production of CAR T cells is the expansion of engineered T cells. To generate enough cells for viable adoptive cell therapy, cells must be robustly stimulated, whi...
Background: Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Despite recent advancements in the treatment of AML, approximately 50% of pat...
Metastatic prostate cancer (mPC) is a phenotypically diverse disease with poor responses to immune based therapeutics. Development of immunotherapeutic strategies for mPC is hampered by the...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
Precision medicine is the paradigm to develop treatments for patients based on molecular-targets that are effective in vivo when administered. In addition to identifying the molecular and ce...
Targeted therapies for cancer are increasingly being developed as an alternative for, and in addition to, immunotherapy. Altered tumor signaling can be exploited to single-out cancer cells f...
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with poor outcome. It is expected to be the leading cause of cancer-related death in 2030. The unique microe...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Operational barriers like complicated workflows and long turnaround times have hindered broad adoption of next-generation sequencing (NGS) in clinical oncology research. The new Ion Torrent...
Learning Objectives: 1. Participants will become familiar with basic aspects of the user experience with the Genexus system 2. Participants will learn about preliminary studies using a targe...
The evolution of clinical trial design in oncology reflects the current clinical paradigm of personalized medicine, weighing both histology and molecularly-defined biomarkers as the pillars...
Follow
